-transparent.png){kind=logo}
Four patients with systemic scleroderma and 1 patient with localized scleroderma were treated with ciclosporin (CS), given in daily doses between 2.2 and 5.6 mg/kg body weight for 3-26 months. Under this medication clinical improvement was observed in 4 patients with partial regression of cutaneous sclerosis and inflammation, healing of fingertip ulcerations or leg ulcers and improvement of articular mobility. However, in 1 patient with rapidly advancing systemic scleroderma a short-term therapy with CS in low doses (2-3 mg/kg body weight) resulted in arterial hypertension and renal dysfunction. Therefore careful selection of patients and close-meshed controls are indicated when CS is considered as anti-inflammatory treatment in scleroderma.
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
December 1991,
Current opinion in rheumatology,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
November 1995,
Current opinion in rheumatology,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
November 1994,
Current opinion in rheumatology,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
March 1972,
Klinicheskaia meditsina,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
March 2001,
Seminars in cutaneous medicine and surgery,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
January 2006,
Clinics in dermatology,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
December 2004,
Current rheumatology reports,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
November 1996,
Current opinion in rheumatology,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
August 2018,
Pediatric clinics of North America,
B Wörle, and
R Hein, and
T Krieg, and
M Meurer
November 1986,
Chinese medical journal,
